A Guide to the Extrapyramidal Side-Effects of Antipsychotic Drugs

D. G. Cunningham Owens

Professor of Clinical Psychiatry, University of Edinburgh, Division of Psychiatry, Royal Edinburgh Hospital, Edinburgh, UK
# Contents

*Preface to the second edition*  vii

## Part 1 – Setting the scene

1. The origins of psychopharma  1
2. Some preliminaries  13

## Part 2 – The syndromes

3. Acute dystonias  35
4. Parkinsonism  68
5. Akathisia  134
6. Tardive dyskinesia  169

## Part 3 – Particular issues

7. Tardive and chronic dystonia  225
8. Special populations  246

## Part 4 – Assessment

9. The clinical examination  265
10. An overview of some standardised recording instruments  276

## Part 5 – Matters arising

11. Involuntary movements and schizophrenia: a limitation to the concept of tardive dyskinesia?  295
12. And finally … the salutary tale of ‘atypicality’  304

*References*  320
*Index*  371
Preface to the second edition

To wait fifteen years for the second edition of any textbook does not speak of the unbridled success of the first. In fact, for a specialist piece in a circumscribed area, the first edition on the present subject did, from the author's perspective at least, gratifyingly well, both in terms of reviews and sales. There is, however, little reward in devoting the effort required to produce a work of this sort (especially when, in academic appraisal terms, books hardly register compared to original research) if fashion has turned against one's topic.

For the past decade, the extrapyramidal side-effects (EPS) of antipsychotic drugs have certainly been out of fashion – up there with flared jeans and disco music. Definitely not cool! With the age of 'atypicality', metabolic issues assumed an ascendancy in the literature that mirrored the decline in EPS. And why should the average practitioner view EPS as anything other than historical exotica when airport departure lounges were clogged with opinion leaders flying the world to spread just that message? A second edition seemed hard to justify.

I was, once upon a time, one of those 'opinion leaders', presenting an upbeat optimism on the subject of EPS tolerability with the new, exciting 'atypical' drugs – until, that is, I became increasingly concerned that the message I was conveying to my colleagues was not entirely consonant with the one my patients were imparting to me. EPS may have slipped beneath consideration elsewhere on the planet, but in the City of Edinburgh, they still seemed to show themselves with brazen disregard to whether antipsychotic choices were 'typical' or 'atypical'. It is true that the bent and shuffling 'old folk' in their twenties who formed the backdrop to my early years in psychiatry seemed to have melted away – but was this novel pharmacology or more prudent therapeutics? Looking beyond the marketing blurbs, it became as hard to see the pharmacological revolution as it was to ignore the intrusive shades of long-time neurological companions.

EPS have not gone away. Of course, the original efficacy studies for newer antipsychotics never claimed they would – only that the liability seemed to be reduced. But over the past few years, a number of pragmatic effectiveness studies have shaken even that assertion. The fact is that EPS are alive and well and living within the profiles of all currently available antipsychotic compounds (and a number of other drug types besides). Indeed, there is an argument presented in the present volume that so long as dopamine antagonism is the target 'anti-psychosis' action, they may to some extent be inevitable. It just depends on how wide you draw the boundaries and how closely you are prepared to look.

So it is time to raise the standard once again and come out fighting to nudge and jostle EPS back to their rightful position at the centre of risk–benefit appraisals for the use of antipsychotic drugs, and hence as issues of paramount importance to all those who prescribe and monitor these, and other, compounds that disrupt nigrostriatal dopamine function. This is nowadays a sizeable constituency. It is not just psychiatrists who need to be alert, but neurologists, primary care physicians, gastroenterologists, geriatricians and those involved in emergency medicine and intensive care, plus a wide range of non-medical professionals, such as community nurses and pharmacists who monitor, and in some countries also themselves prescribe, such compounds.

Second editions usually involve a degree of updating, little more. The present work has, however, been substantially (>80%) rewritten. A decade and a half is a long time in medical research and would, in itself, justify more than mere tinkering. What is striking, however, is the change in the landscape available for review now, compared to the late 1990s. Over the past decade or two, basic research on EPS has shrunk to a trickle compared to its heyday in the 1980s and early 1990s, with psychiatry contributing just the occasional splash. This can only have come from a genuine belief that the
Preface to the second edition

problem was over, the risks ameliorated. If so, it is iron-
icial that such evaporation of interest should take place
when so much has been happening in movement disor-
ders in general, for there was a time when the two were
inextricable – research in the drug domain feeding into
research on idiopathic disorders, and vice versa. It is
less the new material we have on EPS that justifies a
rewrite than this expansion on the neurological front,
which brings large cuts of comparative meat to the

In addition, however, the original version of the
present work adopted an overwhelmingly clinical
approach – an ‘in-my-experience’ and ‘here-is-the-
evidence’ approach. In these days of evidence-based
medicine and readerships raised on it, this is less
than acceptable. So the emphasis is inverted this time
round – to ‘here-is-the-evidence’ and ‘in my experi-
ence’ – though one must admit that the guidance
and recommendations – indeed, the literature itself –
remain firmly filtered through my own clinical experi-
ience. Experience, of course, means little if it has not
translated into that most precious of medical commod-
ities, expertise – that little ‘extra’ the years of experience
offer one the opportunity to accrue. So it is my hope
that four decades of clinical experience burnish, rather
than dull, the facts.

Evidence-based practice exerts a further pull, for
it fundamentally challenges what exactly a ‘textbook’
should be. Facts are clearly important but in a world
where all facts are available at the click of a mouse,
more is now demanded. In addition to facts, the pre-
sent work aims to provide some degree of context in,
for example, the historical frame of reference in which
antipsychotic drugs came to us, and in comparisons
and contrasts with comparable neurological disorders.
But neither do we shy away from controversies that still
exist – indeed, are perhaps flourishing in an environ-
ment where ‘atypical’ has become part of the psycho-
pharmacological vernacular, yet looks increasingly
frail and insubstantial. With regard to the opinion
presented in relation to these controversies the reader
may not agree with everything in the following pages,
but I will be content if sufficient has been presented to
inform his or her indignation.

Finally, one should never be loath to acknowledge
the role one’s teachers played in honing that expertise
and it is a pleasure to record the debt I owe to all the
many hundreds of patients who, over a now rather long
career, have allowed me to learn from their misfor-
tunes, and to the late Professor David Marsden, whose
charismatic teaching style I have, through these years,
tried but so often failed, to emulate. It is also a pleas-
ure to offer gratitude to my long-standing friend and
colleague, Professor Eve Johnstone, for her invaluable
comments on various drafts of this work.